Your session is about to expire
← Back to Search
Behavioral Intervention
Contingency Management for Cannabis Use in HIV
N/A
Recruiting
Led By Chukwuemeka N Okafor, PhD, MPH
Research Sponsored by The University of Texas Health Science Center at San Antonio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Must not have
Diagnosed or receiving treatment for a current major depressive or anxiety disorder
Diagnosed with any current alcohol or substance use disorder (excluding nicotine) using the Structured Clinical Interview for Clinical Disorders (SCID) Interview (22)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28-days
Awards & highlights
Summary
This trial will test the feasibility and impact of 28 days of abstinence from cannabis use on symptoms of depression and anxiety, pain, sleep, cannabis use withdrawal, HIV viral load and biomarkers of systemic inflammation among people with HIV who use cannabis regularly.
Who is the study for?
This trial is for people living with HIV who use cannabis at least weekly, can speak English, and are willing to try not using cannabis for 28 days while attending study visits. They must have a positive urine test for cannabis but cannot be seeking treatment for its use or have any major substance abuse disorders (except nicotine), psychiatric conditions, or other issues that could make the trial unsafe.
What is being tested?
The study tests if giving money as motivation helps participants stop using cannabis for 28 days. It looks at how quitting affects their depression, anxiety, pain, sleep quality, withdrawal symptoms from stopping cannabis use, HIV viral load levels and inflammation markers in the body.
What are the potential side effects?
Since this trial involves abstaining from cannabis rather than taking new medications, it does not list specific side effects like drug trials do. However, participants might experience withdrawal symptoms such as irritability or difficulty sleeping.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am currently diagnosed with or being treated for depression or anxiety.
Select...
I do not have a current alcohol or substance use disorder.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 28-days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28-days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Sustained cannabis abstinence for 28-days
Trial Design
1Treatment groups
Experimental Treatment
Group I: Contingency Management - CannabisExperimental Treatment1 Intervention
Participants will be incentivized following biochemical verification (from urine samples) of cannabis abstinence.
Find a Location
Who is running the clinical trial?
The University of Texas Health Science Center at San AntonioLead Sponsor
467 Previous Clinical Trials
91,719 Total Patients Enrolled
The University of Texas Health Sciences Center, HoustonUNKNOWN
National Institute on Drug Abuse (NIDA)NIH
2,543 Previous Clinical Trials
3,249,331 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I do not have a current alcohol or substance use disorder.You are currently using cannabis and are not willing to stop using it during the study.You have used cannabis at least once a week for the six months before agreeing to participate in the study.You are willing to stop using cannabis for 28 days and attend eight study visits over six weeks.You are able to speak and understand English well.You are currently being treated for addiction to drugs, including cannabis.I am currently diagnosed with or being treated for depression or anxiety.
Research Study Groups:
This trial has the following groups:- Group 1: Contingency Management - Cannabis
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Human Immunodeficiency Virus Infection Patient Testimony for trial: Trial Name: NCT04866004 — N/A
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger